Search Results - "Sikora, M J"

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study by Hertz, D. L., Kidwell, K. M., Hilsenbeck, S. G., Oesterreich, S., Osborne, C. K., Philips, S., Chenault, C., Hartmaier, R. J., Skaar, T. C., Sikora, M. J., Rae, J. M.

“…Purpose A number of studies have tested the hypothesis that breast cancer patients with low-activity CYP2D6 genotypes achieve inferior benefit from tamoxifen…”
Get full text

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients by Rae, J M, Sikora, M J, Henry, N L, Li, L, Kim, S, Oesterreich, S, Skaar, T C, Nguyen, A T, Desta, Z, Storniolo, A M, Flockhart, D A, Hayes, D F, Stearns, V

“…The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of…”
Get full text

Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth by Sikora, MJ, Rae, JM, Johnson, MD, Desta, Z

“…Objectives Efavirenz‐based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we tested the hypothesis that efavirenz induces…”
Get full text

High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues by Sikora, M J, Thibert, J N, Salter, J, Dowsett, M, Johnson, M D, Rae, J M

“…Single-nucleotide polymorphisms (SNPs) can be assayed using DNA isolated from archival formalin-fixed, paraffin-embedded (FFPE) samples, making retrospective…”
Get full text

Abstract P3-07-04: WNT4 mediates endocrine response and resistance in invasive lobular carcinoma cells by Sikora, MJ, Oesterreich, S

“…Abstract Invasive lobular carcinoma (ILC) is a breast cancer subtype affecting ~30,000 U.S. women annually. Over 90% of ILC are estrogen receptor…”
Get full text

Abstract P3-04-02: Invasive lobular carcinoma cell lines utilize WNT4 signaling to mediate estrogen-induced growth by Sikora, MJ, Oesterreich, S

“…Abstract Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing 10-15% of newly diagnosed breast tumors. Over 90% of ILC are…”
Get full text

Abstract P3-06-03: Copy number analysis identifies ESR1 and MDM4 as drivers of progression in invasive lobular breast carcinoma by Atkinson, JM, Cao, L, Basudan, A, Sikora, MJ, Bahreini, A, Tasdemir, N, Jankowitz, RC, McAuliffe, PF, Dabbs, D, Haupt, S, Haupt, Y, Peter Lucas, PC, Lee, AV, Oesterreich, S

“…Abstract Background: Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer after invasive ductal carcinoma (IDC)…”
Get full text

Abstract P5-04-21: FGFR4 is a novel druggable target for recurrent ER-positive breast cancers by Levine, KM, Ding, K, Priedigkeit, N, Sikora, MJ, Tasdemir, N, Zhu, L, Tseng, GC, Jankowitz, RC, Dabbs, DJ, McAuliffe, PF, Lee, AV, Oesterreich, S

“…Abstract Background Breast cancer recurrence is a major clinical problem for estrogen receptor positive (ER+) disease, even decades after initial surgery…”
Get full text

P100 Genetic Alterations in p53 in Head and Neck Cancer Cell Lines Change Cisplatin Sensitivity by Bauer, J. A, Brenner, J, Sikora, M. J, Bradford, C. R, Carey, T. E

Get full text

Abstract P3-04-02: Differential turnover of estrogen receptor alpha in invasive lobular carcinoma by Sreekumar, S, Levine, K, Sikora, MJ, Boone, D, Dabbs, DJ, Lee, AV, Jankowitz, RC, Oesterreich, S

“…Abstract Background: Invasive lobular carcinoma (ILC) accounts for 10-15% of invasive breast cancers diagnosed annually. There is increasing evidence that…”
Get full text

Abstract PD4-09: Combination FGFR4 and ER-targeted therapy for invasive lobular carcinoma by Levine, KM, Chen, J, Sikora, MJ, Tasdemir, N, Priedigkeit, N, Tseng, GC, Puhalla, SL, Jankowitz, RC, Dabbs, DJ, McAuliffe, PF, Lee, AV, Oesterreich, S

“…Abstract Background Invasive Lobular Carcinoma (ILC) is an understudied subtype of breast cancer that requires novel therapies in the advanced setting…”
Get full text

Abstract P4-05-02: Differential regulation of ER protein-turnover in invasive lobular carcinoma cells by Jankowitz, RC, Sreekumar, S, Levine, KM, Meier, C, Sikora, MJ, Basudan, A, Boone, D, Dabbs, DJ, Jacobsen, B, Lee, AV, Oesterreich, S

“…Abstract Background: Invasive lobular breast carcinoma (ILC) accounts for 10-15% of breast cancers diagnosed annually. ILCs are more likely to be positive…”
Get full text

Abstract PD7-03: Investigating cortactin as a genetic driver of disease progression in invasive lobular carcinoma by Tasdemir, N, Sikora, MJ, Zhu, L, Levine, KM, Scott, J, Basudan, A, Sflomos, G, Sreekumar, S, Bossart, EA, Elishaev, E, Chandran, UR, Tseng, GC, Jankowitz, RC, Dabbs, DJ, McAuliffe, PF, Brisken, C, Davidson, NE, Oesterreich, S

“…Abstract Invasive lobular carcinoma (ILC) is the second most common type of breast cancer following invasive ductal carcinoma (IDC) and accounts for 10-15% of…”
Get full text

S110 (−)-Gossypol, a BH3 Mimetic and Inducer of Apoptosis in Head and Neck Cancer Cells, Is Oxidized and Deactivated by ROS by Sikora, M. J, Bauer, J. A, Brenner, J. C, Carey, T. E, Bradford, C. R

Get full text

Abstract P6-04-20: Endocrine resistance in invasive lobular carcinoma cells parallels unique estrogen-mediated gene expression by Sikora, MJ, Luthra, S, Chandran, UR, Dabbs, DJ, Welm, AL, Oesterreich, S

“…Abstract Invasive lobular carcinoma (ILC) represents ∼10% of newly diagnosed breast tumors, accounting for ∼30,000 cases annually in the US. However, ILC has…”
Get full text

Abstract P5-09-03: Endocrine response in invasive lobular carcinoma is characterized by unique estrogen-mediated gene expression and de novo tamoxifen resistance by Sikora, MJ, Cooper, KL, Bahreini, A, Luthra, S, Chandran, UR, Wang, G, Dabbs, DJ, Welm, AL, Oesterreich, S

“…Abstract Invasive lobular carcinoma (ILC) represents ∼10% of newly diagnosed breast tumors, or ∼30,000 cases annually in the US. However, ILC-specific…”
Get full text

Abstract P3-05-14: A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma by Jankowitz, RC, McAuliffe, PF, Sikora, MJ, Butler, L, Ahrendt, G, Johnson, R, Diego, E, Bonaventura, M, Puhalla, S, Lembersky, B, Clark, B, Brufsky, A, Kurland, BF, Davidson, NE, Dabbs, DJ, Oesterreich, S

“…Abstract Background: Patients with invasive lobular carcinoma (ILC) would be expected to have favorable outcomes compared to patients with invasive ductal…”
Get full text

Abstract P4-02-01: Correlations between Genetic Variants in CYP2D6 and UGT2B7 and Survival in Breast Cancer Patients Treated with or without Tamoxifen: Results from a Large Cohort Study by Oesterreich, S, Hilsenbeck, SH, Skaar, T, Hartmaier, RJ, Flockhart, DA, Sikora, MJ, Osborne, CK, Rae, JM

“…Abstract Background. A large number of studies testing the hypothesis that genetic variants in drug metabolizing enzymes can influence breast cancer patient…”
Get full text